sGC stimulators of sGC activators in combination with PDE5 inhbitors for the treatment of erectile dysfunction

Details for Australian Patent Application No. 2010205931 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Sandner, Peter; Stasch, JohannesPeter; Bottcher, Michael-Friedrich

Agent Davies Collison Cave

Pub. Number AU-A-2010205931

PCT Pub. Number WO2010/081647

Priority 09002177.5 17.02.09 EP; 09000619.8 17.01.09 EP

Filing date 7 January 2010

Wipo publication date 22 July 2010

International Classifications

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/195 (2006.01)

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/53 (2006.01) - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61K 31/5377 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 15/00 (2006.01) Drugs for genital or sexual disorders

Event Publications

28 July 2011 PCT application entered the National Phase

  PCT publication WO2010/081647 Priority application(s): WO2010/081647

29 September 2011 Amendment Made

  The nature of the amendment is: Amend the invention title to read sGC stimulators of sGC activators in combination with PDE5 inhibitors for the treatment of erectile dysfunction

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010205940-Coupled gas/steam turbine

2010205907-Self-retracting lifeline